- Conditions
- Acute Myeloid Leukemia
- Interventions
- Ziftomenib, Olutasidenib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
Condition Directory
Acute Myeloid Leukemia clinical trials
Directory of U.S. ClinicalTrials.gov public records for Acute Myeloid Leukemia. Browse Acute Myeloid Leukemia recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 29, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
2504
Shown on this page
12
Current sort
Recently updated
Condition scope
Acute Myeloid Leukemia
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Acute Myeloid Leukemia studies are organized in the registry
AML records split between newly diagnosed and relapsed/refractory settings, and a meaningful share are defined by a mutation — FLT3, IDH1, IDH2, NPM1 — that appears verbatim in titles. Age language (“older adults,” “unfit for intensive chemotherapy”) is also common and reflects how the field organizes its studies.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 241–252 of 2,504 matching trials for Acute Myeloid Leukemia.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
- Interventions
- Iadademstat, Gilteritinib Oral Tablet
- Drug
- Lead sponsor
- Oryzon Genomics S.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 13
- States / cities
- Gilbert, Arizona • Tucson, Arizona • Miami, Florida + 9 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Fludarabine, Cytarabine, Gemtuzumab Ozogamicin, Azacitidine, Venetoclax
- Drug
- Lead sponsor
- PedAL BCU, LLC
- Other
- Eligibility
- 29 Days to 21 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 40 more
- Conditions
- Acute Myeloid Leukemia, Pediatric AML
- Interventions
- Idarubicin Hydrochloride, Fludarabine, Cytarabine (Ara-C), Venetoclax, Etoposide, Asparaginase Erwinia Chrysanthemi (recombinant), Intrathecal triple, SOC
- Drug · Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 1 Month to 30 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Interventions
- Cytarabine, Flotetuzumab
- Drug · Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 20 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 16 more
- Conditions
- AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia
- Interventions
- Rabbit Anti thymocyte globulin, Busulfan, Fludarabine, Thiotepa, Melphalan, TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft, memory-like natural killer cells, IL-2, Plerixafor, Granulocyte Colony-Stimulating Factor, CliniMACS
- Drug · Biological · Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Secondary Acute Myeloid Leukemia
- Interventions
- Venetoclax, FLAG or CLAG Protocol
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Actinium Ac 225 Lintuzumab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Venetoclax
- Radiation · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Enasidenib Mesylate
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 2
- States / cities
- Duarte, California • Tampa, Florida
- Conditions
- Acute Leukemia, Myelodysplastic Syndrome
- Interventions
- QUAIL-100
- Biological
- Lead sponsor
- Laguna Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Months to 39 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome
- Interventions
- Monzosertib, Posaconazole, Isavuconazole
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloid Malignancies, MDS, Inherited Bone Marrow Failure Syndrome, Myeloid Neoplasm, Aml
- Interventions
- Decitabine, Filgrastim
- Drug
- Lead sponsor
- Franziska Wachter
- Other
- Eligibility
- 1 Year to 39 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
About this Acute Myeloid Leukemia clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Acute Myeloid Leukemia as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Acute Myeloid Leukemia.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Acute Myeloid Leukemia.